

PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) REF. D	OCTOR : DR. BANK OF	BARODA	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : <b>0290XB001</b> PATIENT ID : PARTM11068 CLIENT PATIENT ID: ABHA NO :	1290 DRAWN RECEIVED :	:42 Years : :10/02/2024 :13/02/2024	
Test Report Status <u>Final</u>	Results	Biological Reference	Interval U	Inits

# MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

# **XRAY-CHEST**

»»	BOTH THE LUNG FIELDS ARE CLEAR
»»	BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR
»»	BOTH THE HILA ARE NORMAL
»»	CARDIAC AND AORTIC SHADOWS APPEAR NORMAL
»»	BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL
»»	VISUALIZED BONY THORAX IS NORMAL
IMPRESSION	NO ABNORMALITY DETECTED
	Dr G.S. Saluja, (MBBS,DMRD) (Consultant Radiologist)

# ECG

ECG

SEVERE SINUS BRADYCARDIA, LEFT WARD AXIS. OTHERWISE NORMAL ECG, COMPARE WITH OLD ECG

# **MEDICAL HISTORY**

RELEVANT PRESENT HISTORY	NOT SIGNIFICANT
RELEVANT PAST HISTORY	PAST H/O HTN- 1 MONTH.
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT
RELEVANT FAMILY HISTORY	F/H/O HYPOTHYROID - MOTHER.
OCCUPATIONAL HISTORY	NOT SIGNIFICANT
HISTORY OF MEDICATIONS	NOT SIGNIFICANT

# **ANTHROPOMETRIC DATA & BMI**

HEIGHT IN METERS	1.72	mts
WEIGHT IN KGS.	87	Kgs
BMI	29	BMI & Weight Status as follo <b>wg</b> /sqmts Below 18.5: Underweight 18.5 - 24.9: Normal



Dr.Arpita Pasari, MD **Consultant Pathologist** 

**PERFORMED AT :** Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008



Page 1 Of 24







PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) REF. DOCTOR : [	DR. BANK OF BARODA
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : <b>0290XB001999</b> PATIENT ID : PARTM110681290 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :42 Years Male DRAWN : RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

25.0 - 29.9: Overweight 30.0 and Above: Obese

### **GENERAL EXAMINATION**

MENTAL / EMOTIONAL STATE	NORMAL
PHYSICAL ATTITUDE	NORMAL
GENERAL APPEARANCE / NUTRITIONAL STATUS	OVERWEIGHT
BUILT / SKELETAL FRAMEWORK	AVERAGE
FACIAL APPEARANCE	NORMAL
SKIN	NORMAL
UPPER LIMB	NORMAL
LOWER LIMB	NORMAL
NECK	NORMAL
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER
THYROID GLAND	NOT ENLARGED
CAROTID PULSATION	NORMAL
TEMPERATURE	AFEBRILE
PULSE	51/MIN, REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT
RESPIRATORY RATE	NORMAL

# CARDIOVASCULAR SYSTEM

ΒP

PERICARDIUM APEX BEAT HEART SOUNDS MURMURS

140/90 MM HG (SUPINE) NORMAL NORMAL NORMAL ABSENT

mm/Hg



Dr.Arpita Pasari, MD **Consultant Pathologist** 

**PERFORMED AT :** Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008



Page 2 Of 24

묷앏





PATIENT NAME : PARTEEK GUPTA (EC-BOBE6	549) REF. DOCTO	<b>DR :</b> DR. BANK OF BARODA
CODE/NAME & ADDRESS : C000138355	ACCESSION NO : 0290XB001999	AGE/SEX : 42 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : PARTM110681290	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	CLIENT PATIENT ID: ABHA NO :	RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
8800465156		
Test Report Status <u>Final</u>	Results Biolo	gical Reference Interval Units

# **RESPIRATORY SYSTEM**

SIZE AND SHAPE OF CHEST	NORMAL
MOVEMENTS OF CHEST	SYMMETRICAL
BREATH SOUNDS INTENSITY	NORMAL
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)
ADDED SOUNDS	ABSENT

# PER ABDOMEN

APPEARANCE	NORMAL
VENOUS PROMINENCE	ABSENT
LIVER	NOT PALPABLE
SPLEEN	NOT PALPABLE
HERNIA	NORMAL

# **CENTRAL NERVOUS SYSTEM**

HIGHER FUNCTIONS	NORMAL
CRANIAL NERVES	NORMAL
CEREBELLAR FUNCTIONS	NORMAL
SENSORY SYSTEM	NORMAL
MOTOR SYSTEM	NORMAL
REFLEXES	NORMAL

### **MUSCULOSKELETAL SYSTEM**

SPINE	Г
JOINTS	I

NORMAL NORMAL

# **BASIC EYE EXAMINATION**



Dr.Arpita Pasari, MD **Consultant Pathologist** 

**PERFORMED AT :** Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008



Page 3 Of 24





### PATIENT NAME : PARTEEK GUPTA (EC-BOBE6549) REF. DOCTOR : DR. BANK OF BARODA CODE/NAME & ADDRESS : C000138355 ACCESSION NO : 0290XB001999 AGE/SEX :42 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : PARTM110681290 : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 10/02/2024 16:17:24 DELHI REPORTED :13/02/2024 15:24:54 ABHA NO : NEW DELHI 110030 8800465156

### Test Report Status Final

Results

Biological Reference Interval Units

CONJUNCTIVA	NORMAL
EYELIDS	NORMAL
EYE MOVEMENTS	NORMAL
CORNEA	NORMAL
DISTANT VISION RIGHT EYE WITHOUT GLASSES	6/6, WITHIN NORMAL LIMIT
DISTANT VISION LEFT EYE WITHOUT GLASSES	6/6, WITHIN NORMAL LIMIT
NEAR VISION RIGHT EYE WITHOUT GLASSES	N-8, SLIGHTLY POOR
NEAR VISION LEFT EYE WITHOUT GLASSES	N-8, SLIGHTLY POOR
COLOUR VISION	NORMAL

# BASIC ENT EXAMINATION

EXTERNAL EAR CANAL	NORMAL
TYMPANIC MEMBRANE	NORMAL
NOSE	NO ABNORMALITY DETECTED
SINUSES	NORMAL
THROAT	NO ABNORMALITY DETECTED
TONSILS	NOT ENLARGED

# **BASIC DENTAL EXAMINATION**

TEETH GUMS DENTAL CHECK-UP DONE HEALTHY

# SUMMARY

RELEVANT HISTORY RELEVANT GP EXAMINATION FINDINGS REMARKS / RECOMMENDATIONS NOT SIGNIFICANT OVERWEIGHT NONE



Dr.Arpita Pasari, MD Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008



View Report







PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) REF. DOCTOR :	DR. BANK OF BARODA
	ACCESSION NO : <b>0290XB001999</b> PATIENT ID : PARTM110681290	AGE/SEX :42 Years Male DRAWN :
DELHI NEW DELHI 110030	CLIENT PATIENT ID: ABHA NO :	RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
8800465156	Results Biological	Reference Interval Units

## FITNESS STATUS

FITNESS STATUS

FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)

### Comments

CLINICAL FINDINGS:-

RAISED FBS.

RAISED HbA1C AND ESTIMATED AVERAG GLUCOSE (EAG)

DYSLIPIDEMIA.

OVER WEIGHT STATUS.

USG SHOWS EARLY FATTY INFILTRATION OF LIVER.

FITNESS STATUS :-

FITNESS STATUS : FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)

ADVICE: WEIGHT REDUCTION, LOW FAT& CARBOHYDRATE DIET AND REGULAR PHYSICAL EXERCISE FOR OVERWEIGHT STATUS AND DYSLIPIDEMIA.

NEED PHYSICIAN CONSULTATION FOR LIFE STYLE MODIFICATION.



Dr.Arpita Pasari, MD Consultant Pathologist



िस्त

Page 5 Of 24

View Report

View Details



UR I



PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) <b>REF. DOCTOR</b> : D	R. BANK OF BARODA
	ACCESSION NO : <b>0290XB001999</b> PATIENT ID : PARTM110681290	AGE/SEX :42 Years Male DRAWN :
DELHI NEW DELHI 110030 8800465156		RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
Test Report Status <u>Final</u>	Results	Units

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN

**Liver** is normal in size, shape with mild increase in parenchymal echotexture. Intra & Extra hepatic biliary radicals are normal. Portal vein and C.B.D are normal in caliber.

Gall Bladder is normal, thin walled & its lumen is echo free.

Spleen is normal in size, shape & echotexture.

Pancreas is normal in size, shape & echotexture.

**Both Kidneys** are normal in size, shape and echotexture. Central pelvicalyceal system is normal. Corticomedullary differentiation is maintained.

**IVC** and **AO** is normal in caliber.No lymphadenopathy.

Urinary Bladder is normal thin walled, there is no calculus.

Prostate is normal in size & echotexture.

**IMPRESSION**- Early fatty infiltration of liver.

Dr G S Saluja (MBBS.DMRD) REG.NO 4005 (Consultant Radiologist)

TMT OR ECHO CLINICAL PROFILE

# **2D ECHOCARDIOGRAPHY**

Dr.Arpita Pasari, MD Consultant Pathologist



Page 6 Of 24

View Report

/iew Details





PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) <b>REF. DOCTOR</b> : D	R. BANK OF BARODA
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : PARTM110681290 CLIENT PATIENT ID:	AGE/SEX :42 Years Male DRAWN : RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
Test Report Status <u>Final</u>	Results	Units

Parasternal long axis, Parasternal short axis at multiple levels, apical 4-C & apical & 5-C views taken.

All cardiac valves are normal in structure & move normally.

All cardiac chambers and great vessels are normal in size.

The left ventricular wall is normal in thickness & contractility.

There is no evidence of any regional wall motion abnormality.

There is no evidence of any vegetation or clot or pericardial effusion.

The calculated LVEF 70%.

# IMPRESSION :-Normal Study -LVEF 70%

# M-MODE ECHOCARDIOGRAPHY

# (1) MITRAL VALVE DIMENSIONS Normal Value

EPSS : mm 2-7 mm

# (2) AORTIC VALVE DIMENSIONS

30

20

Aortic Root Left atrium Cusp Opening

: mm 2 40 : mm : mm

20-37 mm ו 19-40 mm 15-26 mm



Dr.Arpita Pasari, MD Consultant Pathologist



Page 7 Of 24

View Repor

View Details





PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) REF. DOCTOR : [	DR. BANK OF BARODA
CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : <b>0290XB001999</b> PATIENT ID : PARTM110681290	AGE/SEX :42 Years Male
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	CLIENT PATIENT ID: ABHA NO :	RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
8800465156		
Test Report Status Final	Results	Units

# (3) LEFT VENTRICULAR DIMENSIONS

DIMENSION	OBSERVED	NORMAL VALUES
LVID (Diastolic) 40	: mm	37-56 mm
LVID (Systolic) 25	: mm	24-42 mm
RVID (Diastolic) 18	: mm	7-23 mm
IVST (Diastolic) 10	: mm	6-11 mm
LVPWT (Diastolic)10	: mm	6-11 mm

# LEFT VENTRICULAR FUNCTION

LVEDV			: ml
LVESV			: ml
EF	70	%	

Dr. Manbeer Singh. (MBBS, PGDCC)

<b>Interpretation(s)</b>

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

FITNESS STATUS-Conclusion on an individual's Fitness, which is commented upon mainly for Pre employment cases, is based on multi factorial findings and does not depend on any one single parameter. The final Fitness assigned to a candidate will depend on the Physician's findings and overall judgement on a case to case basis, details of the candidate's past and personal history as well as the comprehensiveness of the diagnostic panel which has been requested for . These are then further correlated with details of the job under consideration to eventually fit the right man to the right job. Basis the above, Agilus diagnostic classifies a candidate's Fitness Status into one of the following categories: • Fit (As per requested panel of tests) – AGILUS Limited gives the individual a clean chit to join the organization, on the basis of the General Physical Examination and

the specific test panel requested for. • Fit (with medical advice) (As per requested panel of tests) - This indicates that although the candidate can be declared as FIT to join the job, minimal problems have



Dr.Arpita Pasari, MD **Consultant Pathologist** 





View Report

Page 8 Of 24

View Details





PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) <b>REF. DOCTOR</b> : D	R. BANK OF BARODA
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	AGE/SEX :42 Years Male DRAWN : RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
Test Report Status <u>Final</u>	Results	Units

been detected during the Pre- employment examination. Examples of conditions which could fall in this category could be cases of mild reversible medical abnormalities such as height weight disproportions, borderline raised Blood Pressure readings, mildly raised Blood sugar and Blood Lipid levels, Hematuria, etc. Most of these relate to sedentary lifestyles and come under the broad category of life style disorders. The idea is to caution an individual to bring about certain lifestyle changes as well as seek a Physician"""'s consultation and counseling in order to bring back to normal the mildly deranged parameters. For all purposes the individual is FIT to join the job. • Fitness on Hold (Temporary Unfit) (As per requested panel of tests) - Candidate's reports are kept on hold when either the diagnostic tests or the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into the physical findings reveal the discovery ophysical findings reveal the test ophysical during because the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into a whole the physical findings reveal the presence of a medical condition which warrants further tests of the physical test opinion of the physical during because the physical findings reveal test opinion and the physical during because the physical test opinion opin Fit, Fit (With Medical Advice), or Unfit category. Conditions which may fall into this category could be high blood pressure, abnormal ECG, heart murmurs, abnormal vision, grossly elevated blood sugars, etc. • Unfit (As per requested panel of tests) - An unfit report by Agilus diagnostic Limited clearly indicates that the individual is not suitable for the respective job profile

e.g. total color blindness in color related jobs.



Dr.Arpita Pasari, MD **Consultant Pathologist** 



Page 9 Of 24

View Report







PATIENT NAME : PARTEEK GUPTA (EC-BOBE65	49) REF. DOCTOR :	DR. BANK OF BARODA
CODE/NAME & ADDRESS : C000138355	ACCESSION NO : 0290XB001999	AGE/SEX : 42 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : PARTM110681290	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 10/02/2024 16:17:24
NEW DELHI 110030	ABHA NO :	REPORTED :13/02/2024 15:24:54
8800465156		
	· · · · · · · ·	
Test Report Status <u>Final</u>	Results Biologica	l Reference Interval Units

HAEMATOLOGY - CBC			
MEDI WHEEL FULL BODY HEALTH CHECK UP AB	OVE 40 MALE		رر
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	15.1	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT	5.09	4.5 - 5.5	mil/µL
WHITE BLOOD CELL (WBC) COUNT	6.65	4.0 - 10.0	thou/µL
PLATELET COUNT	288	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	42.8	40 - 50	%
MEAN CORPUSCULAR VOLUME (MCV)	84.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	29.7	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	35.7 High	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	11.9	11.6 - 14.0	%
MENTZER INDEX	16.5		
MEAN PLATELET VOLUME (MPV)	9.9	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	66	40 - 80	%
LYMPHOCYTES	27	20 - 40	%
MONOCYTES	02	2 - 10	%
EOSINOPHILS	05	1 - 6	%
BASOPHILS	00	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT	4.39	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT	1.80	1 - 3	thou/µL
ABSOLUTE MONOCYTE COUNT	0.13 Low	0.20 - 1.00	thou/µL
ABSOLUTE EOSINOPHIL COUNT	0.33	0.02 - 0.50	thou/µL



Dr.Arpita Pasari, MD Consultant Pathologist



Page 10 Of 24

View Report





PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) REF.	DOCTOR : DR. BANK OF BARODA
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : <b>0290XB00</b> PATIENT ID : PARTM1106 CLIENT PATIENT ID: ABHA NO :	
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units

<b>Interpretation(s)</b>

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020)

106504

This ratio element is a calculated parameter and out of NABL scope.



Dr.Arpita Pasari, MD **Consultant Pathologist** 



**e** 9 ų,

View Report



View Details





PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	19) REF. DOCTOR :	DR. BANK OF BARODA
CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : <b>0290XB001999</b> PATIENT ID : PARTM110681290	AGE/SEX :42 Years Male
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	CLIENT PATIENT ID: ABHA NO :	RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

	HAEMATOLOGY							
MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE								
ERYTHROCYTE SEDIMENTATION RATE (ESF BLOOD	R),EDTA							
E.S.R	10	0 - 14	mm at 1 hr					
METHOD : MODIFIED WESTERGREN								
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD								
HBA1C	5.9 High	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%					
METHOD : HPLC TECHNOLOGY		(						
ESTIMATED AVERAGE GLUCOSE(EAG)	122.6 High	< 116.0	mg/dL					

<b>Interpretation(s)</b> ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-<b>TEST DESCRIPTION</b> :

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. <b>TEST INTERPRETATION</b>

<b>Increase</b> in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR<b>(>100 mm/hour)</b> in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. <b>Decreased</b> in: Polycythermia vera, Sickle cell anemia

<b>LIMITATIONS</b>

<b>False elevated</b> ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

<b>False Decreased<//>

: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibringen, Very high WBC counts, Drugs(Quinine,

salicylates)

Dr.Arpita Pasari, MD **Consultant Pathologist** 





Page 12 Of 24



PATIENT NAME : PARTEEK GUPTA (EC-BOBE65	49)	<b>REF. DOCTOR :</b>	or. Bank o	F BARODA	
CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NC	) : <b>0290XB001999</b> : PARTM110681290	AGE/SEX DRAWN	:42 Years :	Male
DELHI NEW DELHI 110030	CLIENT PATIEN ABHA NO	T ID: :		:10/02/2024 :13/02/2024	
8800465156	Desulte	Distantian	Deferre	- Tuto	1 14
Test Report Status Final	Results	Biological	Reference	e Interval l	Jnits

REFERENCE

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-<b>Used For</b>:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-

controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

<b>HbA1c Estimation can get affected due to :</b>
1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate pattorm (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy



Dr.Arpita Pasari, MD **Consultant Pathologist** 







View Details





PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) REF. DOCTOR : D	R. BANK OF BARODA
	ACCESSION NO : <b>0290XB001999</b> PATIENT ID : PARTM110681290	AGE/SEX : 42 Years Male DRAWN :
DELTI		RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
8800465156		

Test Report Status Final

Results

**Biological Reference Interval** Units

# IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP TYPE O METHOD : TUBE AGGLUTINATION TYPE RH TYPE POSITIVE

METHOD : TUBE AGGLUTINATION

<b>Interpretation(s)</b>

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.



Dr.Arpita Pasari, MD Consultant Pathologist



View Report

ा स

view Details





PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) <b>REF. DOCTOR</b> : D	R. BANK OF BARODA
CODE/NAME & ADDRESS : C000138355	ACCESSION NO : 0290XB001999	AGE/SEX :42 Years Male
	PATIENT ID : PARTM110681290	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 10/02/2024 16:17:24
NEW DELHI 110030	ABHA NO :	REPORTED :13/02/2024 15:24:54
8800465156		
	•	•

Test	Report	Status	<u>Final</u>
	•		

Results

**Biological Reference Interval** Units

BIOCHEMISTRY						
MEDI WHEEL FULL BODY HEALTH CHECK UP A	BOVE 40 MALE					
GLUCOSE FASTING, FLUORIDE PLASMA						
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	100 High	74 - 99	mg/dL			
GLUCOSE, POST-PRANDIAL, PLASMA						
PPBS(POST PRANDIAL BLOOD SUGAR)	113	Normal: < 140, Impaired Glucose Tolerance:140-199 Diabetic > or = 200	mg/dL			
METHOD : HEXOKINASE						
LIPID PROFILE WITH CALCULATED LDL						
CHOLESTEROL, TOTAL	218 High	Desirable: <200 BorderlineHigh : 200-239 High : > or = 240	mg/dL			
METHOD : OXIDASE, ESTERASE, PEROXIDASE	114	Desirable: < 150 Borderline High: 150 - 199 High: 200 - 499 Very High : > or = 500	mg/dL			
METHOD : ENZYMATIC ASSAY HDL CHOLESTEROL	46	< 40 Low > or = 60 High	mg/dL			
METHOD : DIRECT- NON IMMUNOLOGICAL CHOLESTEROL LDL	149 High	Adult levels: Optimal < 100 Near optimal/above optimal 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL :			
NON HDL CHOLESTEROL	172 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189	mg/dL			



Dr.Arpita Pasari, MD **Consultant Pathologist** 

**PERFORMED AT :** Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008 Page 15 Of 24







PATIENT NAME : PARTEEK GUPTA (EC-BOBE	6549) REF. DOCTOR	: DR. BANK OF BARODA
CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>0290XB001999</b> PATIENT ID : PARTM110681290 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :42 Years Male DRAWN : RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
Test Report Status <u>Final</u>	Results Biologic	cal Reference Interval Units

		High: 190 - 219 Very high: > or = 220	
METHOD : CALCULATED VERY LOW DENSITY LIPOPROTEIN METHOD : CALCULATED	22.8	< or = 30	mg/dL
CHOL/HDL RATIO	4.7 High	3.3 - 4.4	
LDL/HDL RATIO	3.2 High	0.5 - 3.0 Desirable/Low Ris 3.1 - 6.0 Borderline/Moder Risk >6.0 High Risk	

## Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Category	· · · · ·					
Extreme risk group	A CAD with	A.CAD with > 1 feature of high risk group				
Extreme fisk group				moun or recurre	ent ACS (within 1 yes	r) despite LDL-C < or =
		polyvascular disease	gn nsk g	group of recurre	int res (within 1 yea	a) despite LDL-C < of
Very High Risk		ed ASCVD 2. Diabetes	with 2	major risk facto	rs or evidence of end	organ damage 3
very mgn Risk		mozygous Hypercholes				organ damage 5.
High Risk					aior risk factor or no	evidence of end organ
		1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary				
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a $>/= 50 \text{ mg/dl}$ 8. Non stenotic carotid plaque					
Moderate Risk	2 major ASCVD risk factors					
Low Risk	0-1 major A	SCVD risk factors				
Major ASCVD (Ath	erosclerotic c	ardiovascular disease)	Risk Fa	actors		
1. Age $>$ or $=$ 45 year	s in males and	l > or = 55 years in fema	ales	3. Current Cig	garette smoking or to	bacco use
2. Family history of premature ASCVD 4. High blood pressure						
5. Low HDL						
Newer treatment goals	s and statin in	itiation thresholds bas	ed on th	e risk categori	es proposed by LAI	in 2020.
Risk Group		<b>Treatment Goals</b>			Consider Drug Th	erapy
		LDL-C (mg/dl)	Non-H	IDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)

H	<b>Risk Stratification</b>	for	ASCVD (	Atherosclerotic cardiovascular disease) by Lipid Association of India
	<b>Risk Category</b>			

Risk Group	<b>Treatment Goals</b>		Consider Drug Therapy		
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)	
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80	
	< OR = 30)	< OR = 60)			
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60	
Very High Risk	<50	<80	>OR= 50	>OR= 80	
High Risk	<70	<100	>OR= 70	>OR=100	

Aspita

Dr.Arpita Pasari, MD **Consultant Pathologist** 

**PERFORMED AT :** Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008

Page 16 Of 24

View Report







PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) <b>REF. DOCTOR</b> : D	PR. BANK OF BARODA
CODE/NAME & ADDRESS : C000138355	ACCESSION NO : 0290XB001999	AGE/SEX : 42 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : PARTM110681290	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 10/02/2024 16:17:24
NEW DELHI 110030	ABHA NO :	REPORTED :13/02/2024 15:24:54
8800465156		
	1	1

Test Report Status	Final	Results	Bio
Test Report Status	<u>rinai</u>	Results	DIU

Biological Reference Interval Units

Moderate Risk<100	mendations from the Lipid A	Association mg/dL mg/dL
*After an adequate non-pharmacological intervention for at least 3 months. References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recom India. Current Vascular Pharmacology, 2022, 20, 134-155. LIVER FUNCTION PROFILE, SERUM BILIRUBIN, TOTAL 0.55 0.0	mendations from the Lipid A	mg/dL
References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice RecommendationIndia. Current Vascular Pharmacology, 2022, 20, 134-155.LIVER FUNCTION PROFILE, SERUMBILIRUBIN, TOTAL0.55O.0 -METHOD : JENDRASSIK AND GROFFBILIRUBIN, DIRECT0.24 HighO.10 -METHOD : DIAZOTIZATIONBILIRUBIN, INDIRECT0.31OTAL PROTEINTOTAL PROTEINALBUMIN5.0GLOBULINQLOBULINALBUMINSACALCULATEDMETHOD : CALCULATEDALBUMIN/GLOBULIN RATIOMETHOD : CALCULATEDALBUMIN/GLOBULIN RATIOMETHOD : CALCULATEDASPARTATE AMINOTRANSFERASE20UPTC(AST/SGOT)	1.2	mg/dL
LIVER FUNCTION PROFILE, SERUM BILIRUBIN, TOTAL 0.55 0.0 - METHOD : JENDRASSIK AND GROFF BILIRUBIN, DIRECT 0.24 High 0.0 - METHOD : DIAZOTIZATION BILIRUBIN, INDIRECT 0.31 0.00 METHOD : CALCULATED TOTAL PROTEIN 7.8 6.4 - METHOD : BIURET ALBUMIN 5.0 3.50 METHOD : BROMOCRESOL GREEN GLOBULIN RATIO 2.8 2.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 1.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 1.0 - METHOD : CALCULATED ASPARTATE AMINOTRANSFERASE 20 UPTO (AST/SGOT)	0.2	-
BILIRUBIN, TOTAL 0.55 0.0 - METHOD : JENDRASSIK AND GROFF BILIRUBIN, DIRECT 0.24 High 0.0 - METHOD : DIAZOTIZATION BILIRUBIN, INDIRECT 0.31 0.00 METHOD : CALCULATED TOTAL PROTEIN 7.8 6.4 - METHOD : BIURET ALBUMIN 5.0 3.50 METHOD : BROMOCRESOL GREEN GLOBULIN 2.8 2.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 1.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 1.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 1.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 0.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 0.0 - METHOD : CALCULATED ASPARTATE AMINOTRANSFERASE 20 UPTO (AST/SGOT)	0.2	-
METHOD : JENDRASSIK AND GROFF         BILIRUBIN, DIRECT       0.24 High       0.0 -         METHOD : DIAZOTIZATION       0.31       0.00         BILIRUBIN, INDIRECT       0.31       0.00         METHOD : DIAZOTIZATION       0.31       0.00         BILIRUBIN, INDIRECT       0.31       0.00         METHOD : CALCULATED       7.8       6.4 -         TOTAL PROTEIN       7.8       6.4 -         METHOD : BIURET       7.8       2.0         ALBUMIN       5.0       3.50         METHOD : BROMOCRESOL GREEN       2.8       2.0 -         GLOBULIN       2.8       2.0 -         METHOD : CALCULATED       1.8       1.0 -         ALBUMIN/GLOBULIN RATIO       1.8       1.0 -         METHOD : CALCULATED       20       UPTOC         ASPARTATE AMINOTRANSFERASE       20       UPTOC         (AST/SGOT)       20       UPTOC	0.2	-
BILIRUBIN, DIRECT0.24 High0.0 -METHOD : DIAZOTIZATION0.310.00BILIRUBIN, INDIRECT0.310.00METHOD : CALCULATED7.86.4 -TOTAL PROTEIN7.86.4 -METHOD : BIURET5.03.50METHOD : BROMOCRESOL GREEN2.82.0 -GLOBULIN2.82.0 -METHOD : CALCULATED1.81.0 -METHOD : CALCULATED2.82.0 -METHOD : CALCULATED2.82.0 -METHOD : CALCULATED1.81.0 -METHOD : CALCULATED2.0 -0.0 -METHOD : CALCULATED1.81.0 -METHOD : CALCULATED1.81.0 -METHOD : CALCULATED2.0 -0.0 -METHOD : CALCULATED1.81.0 -METHOD : CALCULATED0.0 -0.0 -<	-	mg/dL
METHOD : DIAZOTIZATION BILIRUBIN, INDIRECT 0.31 0.00 METHOD : CALCULATED TOTAL PROTEIN 7.8 6.4 - METHOD : BIURET ALBUMIN 5.0 3.50 METHOD : BROMOCRESOL GREEN GLOBULIN 2.8 2.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 1.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 2.0 UPTO ASPARTATE AMINOTRANSFERASE 20 UPTO (AST/SGOT)	-	mg/dL
BILIRUBIN, INDIRECT       0.31       0.00         METHOD : CALCULATED       7.8       6.4         METHOD : BIURET       7.8       6.4         ALBUMIN       5.0       3.50         METHOD : BROMOCRESOL GREEN       2.8       2.0         GLOBULIN       2.8       2.0         METHOD : CALCULATED       1.8       1.0         ALBUMIN/GLOBULIN RATIO       1.8       1.0         METHOD : CALCULATED       20       UPTO         ASPARTATE AMINOTRANSFERASE       20       UPTO	1.00	
METHOD : CALCULATED TOTAL PROTEIN 7.8 6.4 - METHOD : BIURET ALBUMIN 5.0 3.50 METHOD : BROMOCRESOL GREEN GLOBULIN 2.8 2.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 1.0 - METHOD : CALCULATED ASPARTATE AMINOTRANSFERASE 20 UPTO (AST/SGOT)	1 00	
TOTAL PROTEIN 7.8 6.4 - METHOD : BIURET ALBUMIN 5.0 3.50 METHOD : BROMOCRESOL GREEN GLOBULIN 2.8 2.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 1.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 2.0 UPTO ASPARTATE AMINOTRANSFERASE 20 UPTO AST/SGOT)	- 1.00	mg/dL
METHOD : BIURET ALBUMIN 5.0 3.50 METHOD : BROMOCRESOL GREEN GLOBULIN 2.8 2.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 1.0 - METHOD : CALCULATED ASPARTATE AMINOTRANSFERASE 20 UPTO (AST/SGOT)	0.2	a /di
ALBUMIN5.03.50METHOD : BROMOCRESOL GREEN2.82.0GLOBULIN2.82.0METHOD : CALCULATED1.81.0ALBUMIN/GLOBULIN RATIO1.81.0METHOD : CALCULATED4.52.0ASPARTATE AMINOTRANSFERASE20UPTO(AST/SGOT)1.51.5	8.3	g/dL
METHOD : BROMOCRESOL GREEN GLOBULIN 2.8 2.0 - METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 1.0 - METHOD : CALCULATED ASPARTATE AMINOTRANSFERASE 20 UPTO (AST/SGOT)	- 5 20	g/dL
GLOBULIN2.82.0METHOD : CALCULATED1.81.0ALBUMIN/GLOBULIN RATIO1.81.0METHOD : CALCULATED20UPTOASPARTATE AMINOTRANSFERASE20UPTOAST/SGOT)2020	- 5.20	g/uL
METHOD : CALCULATED ALBUMIN/GLOBULIN RATIO 1.8 1.0 - METHOD : CALCULATED ASPARTATE AMINOTRANSFERASE 20 UPTO (AST/SGOT)	4.1	g/dL
METHOD : CALCULATED ASPARTATE AMINOTRANSFERASE 20 UPTC (AST/SGOT)		5,
ASPARTATE AMINOTRANSFERASE 20 UPTC (AST/SGOT)	2.0	RATIO
AST/SGOT)		
	) 40	U/L
METHOD : UV WITH P5P		
ALANINE AMINOTRANSFERASE (ALT/SGPT) 31 UP T	0.45	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) 31 UP T	J 45	0/L
ALKALINE PHOSPHATASE 92 40 -	170	U/L
METHOD : PNPP	125	0/2
GAMMA GLUTAMYL TRANSFERASE (GGT) 33 8 - 6		U/L
METHOD : G-GLUTAMYL-CARBOXY-NITROANILIDE	1	
	1	1171
METHOD : ENZYMATIC LACTATE - PYRUVATE(IFCC)	1 - 225	U/L

# **BLOOD UREA NITROGEN (BUN), SERUM**

BLOOD UREA NITROGEN	14	6 - 20	mg/dL
METHOD : UREASE KINETIC			



Dr.Arpita Pasari, MD Consultant Pathologist



Page 17 Of 24





PATIENT NAME : PARTEEK GUPTA (EC-BOBE6549) REF. DOCTOR : DR. BANK OF BARODA				
CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>029</b> PATIENT ID : PAR CLIENT PATIENT ID: ABHA NO :	TM110681290 DRAWN : RECEIVED : 1	2 Years Male .0/02/2024 16:17:24 .3/02/2024 15:24:54	
Test Report Status <u>Final</u>	Results	Biological Reference I	nterval Units	
CREATININE, SERUM				
CREATININE METHOD : ALKALINE PICRATE KINETIC JAFFES	1.00	0.70 - 1.20	mg/dL	
BUN/CREAT RATIO				
BUN/CREAT RATIO METHOD : CALCULATED	14.00	5.0 - 15.0		
URIC ACID, SERUM				
URIC ACID METHOD : URICASE/CATALASE UV	3.5	3.5 - 7.2	mg/dL	
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN METHOD : BIURET	7.8	6.4 - 8.3	g/dL	
ALBUMIN, SERUM				
ALBUMIN METHOD : BROMOCRESOL GREEN	5.0	3.5 - 5.2	g/dL	
GLOBULIN				
GLOBULIN	2.8	2.0 - 4.1	g/dL	
ELECTROLYTES (NA/K/CL), SERUM SODIUM, SERUM METHOD : DIRECT ION SELECTIVE ELECTRODE	145.2	136.0 - 146.0	mmol/L	



Dr.Arpita Pasari, MD **Consultant Pathologist** 

Page 18 Of 24



View Details







PATIENT NAME : PARTEEK GUPTA (EC-BO	BE6549)	REF. DOCTOR : DR. BANK (	DF BARODA
CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>029</b> PATIENT ID : PAR <sup>:</sup> CLIENT PATIENT ID: ABHA NO :	M110681290 DRAWN RECEIVED	:42 Years Male : 0 :10/02/2024 16:17:24 0 :13/02/2024 15:24:54
Test Report Status <u>Final</u>	Results	Biological Reference	ce Interval Units
POTASSIUM, SERUM METHOD : DIRECT ION SELECTIVE ELECTRODE	4.31	3.50 - 5.10	mmol/L
CHLORIDE, SERUM	104.5	98.0 - 106.0	mmol/L

METHOD : DIRECT ION SELECTIVE ELECTRODE

### Interpretation(s)

Sodium	Potassium	Chloride
Sodium Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism,metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison' s disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

<b>Interpretation(s)</b>

GLUCOSE FASTING, FLUORIDE PLASMA-<b>TEST DESCRIPTION</b>

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

<b>Increased in</b>:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.<b>Decreased in </b>:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy (adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

<b>NOTE:</b> While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed,Alimetary Hypoglycemia,Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin



Dr.Arpita Pasari, MD **Consultant Pathologist** 



View Details

Page 19 Of 24



PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) REF. DOCTOR : [	PR. BANK OF BARODA
CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>0290XB001999</b> PATIENT ID : PARTM110681290 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :42 Years Male DRAWN : RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
Test Report Status Final	Results Biological	Reference Interval Units

# treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

<b>>Bilirubin</b> is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice.<b>Elevated levels</b> results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased more than unconjugated (indirect) bilirubin in Viral hepatitis), Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

(b) AST (b) is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

<>>ALP</b> is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

<b>GGT</b> is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that

increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. <b>Total Protein</b> also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

<b>Albumin</b> is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing

enteropathy, Burns, hemodilution, increased vascular permeability or decreased spin term vascular permeability or decreased spin teropermeability or decreas

<b>Causes of decreased</b> level include Liver disease, SIADH. CREATININE, SERUM-<b>Higher than normal level may be due to:</b>

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)
 Lower than normal level may be due to:
 Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-ab>Causes of Increased levels: </b>-Low Zinc intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome <br/>
<

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. <b>Higher-than-normal levels may be due to:</b> Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. <b>comparing the second s Nephrotic syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood

serum protein. <b>Low blood albumin levels (hypoalbuminemia) can be caused by: </b> Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.



Dr.Arpita Pasari, MD **Consultant Pathologist** 

Page 20 Of 24





View Details





PATIENT NAME : PARTEEK GUPTA (EC-BOBE	E6549) R	EF. DOCTOR	DR. BANK OF BARODA
CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>0290X</b> PATIENT ID : PARTM CLIENT PATIENT ID: ABHA NO :	<b>B001999</b> 110681290	AGE/SEX :42 Years Male DRAWN : RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
Test Report Status <u>Final</u>	Results	Biologic	al Reference Interval Units
CLII	NICAL PATH - URINALYSI	S	
MEDI WHEEL FULL BODY HEALTH CHECK UP	ABOVE 40 MALE		
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
APPEARANCE	CLEAR		
CHEMICAL EXAMINATION, URINE			
РН	6.0	4.7 - 7.	5
SPECIFIC GRAVITY	1.010	1.003 -	1.035
PROTEIN	NOT DETECTED	NOT DE	TECTED
GLUCOSE	NOT DETECTED	NOT DE	TECTED
KETONES	NOT DETECTED	NOT DE	TECTED
BLOOD	NOT DETECTED	NOT DE	TECTED
BILIRUBIN	NOT DETECTED	NOT DE	TECTED
UROBILINOGEN	NORMAL	NORMAI	-
NITRITE	NOT DETECTED	NOT DE	TECTED

# MICROSCOPIC EXAMINATION, URINE

LEUKOCYTE ESTERASE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	2-3	0-5	/HPF
EPITHELIAL CELLS	1-2	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	
REMARKS	Please note that all the u	rinary findings are confirmed ma	nually as well.

NOT DETECTED

NOT DETECTED

Aspita

Dr.Arpita Pasari, MD Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008 Page 21 Of 24









PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) REF. [	DOCTOR : DR. BANK OF	BARODA
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : <b>0290XB001</b> PATIENT ID : PARTM11068 CLIENT PATIENT ID: ABHA NO :	31290 DRAWN RECEIVED	:42 Years Male : :10/02/2024 16:17:24 :13/02/2024 15:24:54
Test Report Status Final	Results	Biological Reference	Toterval Units

### Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

B

Dr.Arpita Pasari, MD **Consultant Pathologist** 

**PERFORMED AT :** Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008 Page 22 Of 24







PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) REF. DOCTOR : [	DR. BANK OF BARODA
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : <b>0290XB001999</b> PATIENT ID : PARTM110681290 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :42 Years Male DRAWN : RECEIVED :10/02/2024 16:17:24 REPORTED :13/02/2024 15:24:54
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE			
MEDI WHEEL FULL BODY HEALTH CHECK	UP ABOVE 40 MALE		
THYROID PANEL, SERUM			
T3 METHOD : CHEMILUMINESCENCE TECHNOLOGY	146.10	80.0 - 200.0	ng/dL
T4 METHOD : CHEMILUMINESCENCE TECHNOLOGY	8.90	5.10 - 14.10	µg/dL
TSH (ULTRASENSITIVE) METHOD : CHEMILUMINESCENCE TECHNOLOGY	2.910	0.270 - 4.200	µIU/mL

### Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Dr.Arpita Pasari, MD **Consultant Pathologist** 





View Details





PATIENT NAME : PARTEEK GUPTA (EC-BOBE654	9) <b>REF. DOCTOR</b> : D	PR. BANK OF BARODA
CODE/NAME & ADDRESS : C000138355	ACCESSION NO : 0290XB001999	AGE/SEX :42 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : PARTM110681290	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 10/02/2024 16:17:24
NEW DELHI 110030	ABHA NO :	REPORTED :13/02/2024 15:24:54
8800465156		

Test Repo	rt Status	<u>Final</u>
-----------	-----------	--------------

Results

**Biological Reference Interval** Units

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> \*\*End Of Report\*\* Please visit www.agilusdiagnostics.com for related Test Information for this accession

### **CONDITIONS OF LABORATORY TESTING & REPORTING**

1. It is presumed that the test sample belongs to the patient 5. named or identified in the test requisition form. 2. All tests are performed and reported as per the clinical safety & technical integrity. 6. Laboratory results should not be interpreted in turnaround time stated in the AGILUS Directory of Services. 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any determine final diagnosis. other unforeseen event. 7. Test results may vary based on time of collection, 4. A requested test might not be performed if: i. Specimen received is insufficient or inappropriate

- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

AGILUS Diagnostics confirms that all tests have been performed or assayed with highest guality standards,

isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to

physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes. 9 In case of queries please call customer care

(91115 91115) within 48 hours of the report.

**Agilus Diagnostics Ltd** 

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



Dr.Arpita Pasari, MD **Consultant Pathologist** 







View Report

